By synthesizing these findings, we hope to offer valuable insights into the optimal use of EGFR TKIs and identify potential areas for further research in the pursuit of a better understanding of the molecular genomics that drive lung cancer and more effective therapies for NSCLC patients. This evidence concerns the gene EGFR and lung cancer.